We were therefore encouraged to see that Meso64-TR3's binding affinity to the MUC16 biomarker was not only retained but resulted in a much more potent cancer drug compared to its full length predecessor on MUC16-positive tumor cells. The gene discussed is MUC16; the disease is cancer.